Commissioners at the U.S. International Trade Commission attempted this week to look past the intellectual property-as-innovation-savior and IP-as-public-health-enemy claims made during the agency’s two-day hearing examining production, supply and access to COVID-19-related tests and treatments, pushing witnesses for information on drug costs, company profits, the effect of a recent World Trade Organization decision and how to define terms and scope, among other issues. The hearing, held on Wednesday and Thursday, included six panels of eight to 12 witnesses from industry...